Blockchain Registration Transaction Record

GeoVax Appeals Nasdaq Delisting, Reaffirms Strategic Focus

GeoVax Labs appeals Nasdaq delisting, reaffirms focus on GEO-MVA vaccine and Gedeptin® cancer therapy. Hearing set for October 13, 2026.

This news matters because GeoVax's ability to maintain its Nasdaq listing is critical for investor confidence and access to capital, which funds its vaccine and immuno-oncology programs. The outcome of the appeal could significantly affect the company's future and, by extension, the development of treatments for mpox, smallpox, and head and neck cancer. Additionally, the progress of GEO-MVA and Gedeptin® addresses global health preparedness and cancer treatment gaps, making this a story with far-reaching implications for public health and biodefense.